Capital Performance Advisors LLP Day One Biopharmaceuticals, Inc. Transaction History
Capital Performance Advisors LLP
- $325 Million
- Q3 2024
A detailed history of Capital Performance Advisors LLP transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Capital Performance Advisors LLP holds 80 shares of DAWN stock, worth $992. This represents 0.0% of its overall portfolio holdings.
Number of Shares
80Holding current value
$992% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding DAWN
# of Institutions
179Shares Held
84.2MCall Options Held
144KPut Options Held
218K-
Ra Capital Management, L.P. Boston, MA7.87MShares$97.6 Million1.53% of portfolio
-
Atlas Venture Life Science Advisors, LLC6.43MShares$79.7 Million11.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.89MShares$73 Million0.0% of portfolio
-
Braidwell LP Stamford, CT4.87MShares$60.4 Million1.92% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$56.2 Million0.0% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $911M
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...